Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00428584 · ClinicalTrials.gov registry record · Phase 3
RNF and Betaseron® Tolerability Study
A Phase 3 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 3
- Development phase
- 129
- Enrollment target
NCT00428584 is a Phase 3 study that has completed, run by EMD Serono. The registered enrollment target is 129 participants.
The verdict
NCT00428584, a Phase 3 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 129 participants
- Enrollment target
Study Summary
To evaluate the tolerability of a new formulation of rebif and Betaseron in subjects with relapsing-remitting multiple sclerosis (RRMS) by comparing the mean change in injection site pain scores from pre-injection to 30 minutes post therapy administration.
Interventions
- DRUG New Formulation of rebif - human interferon beta-1a
- DRUG Interferon beta -1b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00428584
The ClinicalTrials.gov registry entry for NCT00428584 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which New Formulation of rebif - human interferon beta-1a is the first listed.
NCT00428584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00428584 about?
NCT00428584 is a clinical study titled "RNF and Betaseron® Tolerability Study". To evaluate the tolerability of a new formulation of rebif and Betaseron in subjects with relapsing-remitting multiple sclerosis (RRMS) by comparing the mean change in injection site pain scores from pre-injection to 30 minutes post therapy administration.
What is the current status of trial NCT00428584?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 129 participants. The study started on 2006-12. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00428584?
The interventions under investigation include: New Formulation of rebif - human interferon beta-1a (DRUG), Interferon beta -1b (DRUG).
Who is sponsoring clinical trial NCT00428584?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.